top
Search terms
Results 1 - 10 of 10 - ordered by :
Escardio

(1) Principal investigator Dr Satoshi Yasuda of the National Cerebral and Cardiovascular Centre, Suita, Japan said: “This data supports the guideline recommendation to use oral anticoagulant ...

Date : 02/09/2019
Escardio

Senior author Professor Philippe Gabriel Steg of Hospital Bichat, Paris, France said: “Treatment with ticagrelor and aspirin also increased major bleeding relative to aspirin alone, but there ...

Date : 01/09/2019
Escardio

Rivaroxaban for stroke or TIA prevention in heart failure patients with sinus rhythm The results of the Commander HF trial about the effects of low dose Rivaroxaban in combination with antiplatelet ...

Date : 08/08/2019
Escardio

AUGUSTUS was a prospective, multicenter, two-by-two factorial, randomized clinical trial, supported by the pharmaceutic industry, including 4614 patients with atrial fibrillation who had a recent ...

Date : 06/05/2019
Escardio

Prof. Zannad points out that, “Rivaroxaban is approved at higher doses to treat conditions such as atrial fibrillation (AF) and venous thromboembolism, but in COMMANDER HF, patients were ...

Date : 28/08/2018
Escardio

Long-term antiplatelet monotherapy after stenting is safe but does not reduce the risk of death or heart attack compared to standard dual antiplatelet therapy, according to late breaking results from ...

Date : 27/08/2018
Escardio

Acute cardiovascular care is the specialty of cardiology dealing with acute problems in need of urgent care including heart attack, cardiac arrest, and acute heart failure, but also other conditions ...

Date : 17/09/2015
Escardio

While the investigator-initiated study showed that DAPT (a combination of aspirin and the P2Y12-receptor blocker clopidogrel) does not decrease the rate of major adverse cardiovascular and ...

Date : 31/08/2015
Escardio

Amsterdam, The Netherlands, 1 September 2013 - Among patients undergoing percutaneous coronary intervention (PCI) with stents, the risk of cardiovascular complications after stopping dual ...

Date : 01/09/2013
Escardio

Barcelona, Spain, 30 August: The presentation of the PLATO (A Study of Platelet Inhibition and Patient Outcomes), showed that ticagrelor (Brilinta®) reduced the rate of cardiovascular (CV) events ...

Date : 30/08/2009